AWS360® has been appointed Asia-Pacific distribution partner for Oxicicledensate®, a patented iron citrate raw material developed by Ti Farma in Italy.
Oxicicledensate® is engineered for very high bioavailability while preventing iron from being released in the gastric tract. That design directly targets the biggest barrier to iron supplementation — the nausea, cramping and constipation associated with conventional forms such as ferrous sulfate — which often reduce how consistently people take their supplements.
Why it matters for brands and manufacturers
Iron deficiency remains one of the most widespread nutritional gaps across Asia Pacific, yet tolerability is a recurring obstacle to compliance. A better-tolerated iron gives brands a genuine point of difference on shelf and in pharmacy, with a story grounded in how the ingredient is absorbed rather than marketing claims alone.
AWS360® will supply Oxicicledensate® with full documentation and can support brands end-to-end — from formulation and dosage-form selection through to manufacturing and regional registration.
To discuss Oxicicledensate® for your range, get in touch with the AWS360® team.
← Back to news